Article

The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 study

2023-02-23

Abstract excerpt

Tumor-associated macrophages (TAM) are critical determinant of resistance to programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade. This phase I study (MEDIPLEX, NCT02777710 ) investigated the safety and efficacy of pexidartinib, a CSF-1R-directed tyrosine kinase inhibitor (TKI), and durvalumab (anti-PD-L1) in patients with advanced colorectal (CRC) and pancreatic (PDAC) carcinoma with the aim to enh...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4e689139-a97a-5934-8b71-aa018ec2e372
DOI: 10.1101/2023.02.15.23285939

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 studyDOI 10.1101/2023.02.15.23285939Read

Decitabine suppresses MDSC-induced immunosuppression through dual functional mechanism and inhibits melanoma metastasisSemantic proximity Read

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trialSemantic proximity Read

Emerging concepts in PD-1 checkpoint biologySemantic proximity Read

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin PathwaySemantic proximity Read

Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsSemantic proximity Read

PD-1 blockade-driven anti-tumor CD8 <sup>+</sup> T cell immunity requires XCR1 <sup>+</sup> dendritic cellsSemantic proximity Read

Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical ImplicationsSemantic proximity Read

Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients.Semantic proximity Read

PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.Semantic proximity Read

CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemiaSemantic proximity Read

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity Read

Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphomaSemantic proximity Read